Last reviewed · How we verify
bevacizumab, carboplatin and paclitaxel
bevacizumab, carboplatin and paclitaxel is a Biologic drug developed by Grupo de Investigación y Divulgación Oncológica. It is currently in Phase 2 development.
At a glance
| Generic name | bevacizumab, carboplatin and paclitaxel |
|---|---|
| Sponsor | Grupo de Investigación y Divulgación Oncológica |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (PHASE3)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bevacizumab, carboplatin and paclitaxel CI brief — competitive landscape report
- bevacizumab, carboplatin and paclitaxel updates RSS · CI watch RSS
- Grupo de Investigación y Divulgación Oncológica portfolio CI
Frequently asked questions about bevacizumab, carboplatin and paclitaxel
What is bevacizumab, carboplatin and paclitaxel?
bevacizumab, carboplatin and paclitaxel is a Biologic drug developed by Grupo de Investigación y Divulgación Oncológica.
Who makes bevacizumab, carboplatin and paclitaxel?
bevacizumab, carboplatin and paclitaxel is developed by Grupo de Investigación y Divulgación Oncológica (see full Grupo de Investigación y Divulgación Oncológica pipeline at /company/grupo-de-investigaci-n-y-divulgaci-n-oncol-gica).
What development phase is bevacizumab, carboplatin and paclitaxel in?
bevacizumab, carboplatin and paclitaxel is in Phase 2.